EXAS Stock Recent News

An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.

Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2024 webcast & conference call details        .

On September 30, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, significantly increased its investment in Exact Sciences Corp (EXAS, Financial), a leader in cancer diagnostics. The firm acquired an additional 8,418,428 shares at a price of $68.12 each, elevating its total holdings to 22,042,464 shares.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved the Cologuard Plus™ test, the company's next generation multitarget stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colorectal cancer (CRC).1 FDA approval was based on findings from the pivotal BLUE-C study, one of the largest prospective.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy. Results were presented today at the European Society for Medical Oncology (ESMO) Congress in an oral presentation tit.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

The mean of analysts' price targets for Exact Sciences (EXAS) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 2024 Healthcare Conference September 5, 2024 3:45 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Brandon Couillard Alright, folks. We'll go ahead and get started.

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?